Experience Of Sickle Cell Patients In Response To Quality Of Healthcare Provided In London assignment sample

• Type Assignment
• Downloads537
• Pages38
• Words9577

Chapter 1: Introduction & Literature Review

1.1 Introduction

Sickle cell disease (SCD) is a genetic disease that affects the shape of the red blood cells resulting in crescent shaped red blood cells formation instead of normal disc shaped. Thus, a patient suffers from severe pains and damages of major organs. In the UK, two third of the people suffering from this disease have either Africa or Caribbean origins. This study especially focuses on SCD patients in London along with the analysis of provisional care provided to them by the healthcare sector. Apart from the government’s effort for healthcare sector improvisation, patients are still facing a lot of challenges to achieve quality care.

Deadlines creeping up? Assignment Writing Help UK is your go-to solution for well-researched, expertly written assignments delivered right on time.

This work aims at analysing SCD patients’ experience with health care services in London. This study will not only demonstrate the issues that patients experience but will also highlight the significance of health care policies that impacts those experiences. This research is based on secondary data, collected via journals, web articles and books. These efforts will help in devising effective plans, implementation of better policies. Likewise, patient experience knowledge will help in effective handling of SCD patients thereby improving their quality of lives (Anie, 2024).

Aim and objectives

• To assess the level of satisfaction of the patients on healthcare services.
• To identify the major problems faced by sickle cell patients.
• To analyse the effect and impact of policies of health care on delivery of care to patients.
• To suggest measures that can be put in place so that the patients can have unique and fulfilling experiences at the facility.

1.1.1 Background

Sickle Cell disease is a hemoglobinopathy; referring to a group of genetic diseases affecting the red blood cells. A common can be seen as increase of blood cholesterol; which is a primary disease of people originating from Africa, the Caribbean, the Middle East, and the Indian subcontinent. The condition affects the red blood cell where the cells are deformed to have a sickle-like structure, as a result of which they cannot transport oxygen well. Blocked blood circulation is a common problem among these cells and results in severe pain as well as other complications.

Currently, the number of people suffering from SCD has been reported to be high in London. For such patients, the National Health Service (NHS) is in charge of their treatment. However, the main problem faced by most of the SCD patients is lack of health care services and facilities provided. One such issue is pain management; which is considered to be a significant problem. Other symptoms include increased sweating, pale or yellowish skin tone, dizziness, headache, and frequent infections. Sometimes, these symptoms can take hours or days to manifest. Hence they are also termed as chronic inflammation (Jastaniah et al. 2023). Oral antibiotics may be required in case of an infection and immediate treatment is necessary in order to avoid pain and further complications. As patients are forced to spend a lot of time waiting in the emergency department, so they complain that doctors and nurses don’t care for them or their pains.

It has also noted that SCD patients are supposed to go for regular check-ups in order to reduce the incidences of complications. Sickle cell clinics in London are present but the patients do not get access to these clinics easily. It is a chronic disease that influences a person’s emotions during his or her lifetime. Some patients develop anxiety and depression due to hospitalizations and prejudice and discrimination from society. However, the patients’ mental health needs are not well met. Such issues as healthcare also raise issues such as inequality in the society. The target population of SCD patients is mainly ethnically diverse, and the research studies suggested that such disease received relatively inferior care as compared to other diseases (Anie, 2024). Many a time people suspect that doctors take their color into consideration while suggesting a treatment plan for their pain management. There is also a support group of patients in London and these help in creating awareness as well as disseminating information.

However, many challenges are present to this date. Training of more and better qualified personnels, quick response time and improved support for mental health are among the improvements required. Information regarding the lives of the SCD patients can therefore assist to enhance their healthcare service delivery.

1.1.2 Historical Background

Sickle cell disease (SCD) was first discovered in 1910 by Sickle cells were discovered in an anemia patient for the first time by James Herrick. It was an anatomical discovery that showed some deformity in the structure of the heart; he also determined that this deformity was hereditary, which fit the model for health within the social model. In the middle of the twentieth century, it was established that what triggered SCD was only the regions that experienced disease of malaria. This is the reason why sickle cell gene carriers avoid developing malaria easily since it has a protective aspect.

The illness also became more recognized in the UK in the 1950s and 1960s. This was because of immigration of people from Africa, the Caribbean and South Asia. Nevertheless, patients’ awareness about this condition was scarce. Around half of the practitioners in the UK did not recognize SCD, and most of the others misdiagnosed it. It was in the 1970s that sickle cell advocacy groups emerged in London. Its increased goal was for the improvement of the extent of healthcare services and to create conscientization for the public. The history of SCD in the diagnosis as an important health issue was discovered in 1981 in the United Kingdom of Great Britain and Northern Ireland (Telfer et al. 2024). Soon other hospitals in London also began to establish their own sickle cell clinics. These clinics offered care to the patients appropriately. However, healthcare inequalities remained. It was revealed that SCD patients were diagnosed with pain and given suboptimal treatment, or got treatment rather late. From the historical developments of SCD in London, it is evident that there has been improvements as well as improvement challenges. In this case, more improvement is required to address the case of this disease in as far as the health of people affected is concerned.

Rationale

Sickle cell disease (SCD) is genetically inherited and is common in several people especially in the African and Caribbean communities residing in London. Similarly, such people struggle to get adequate healthcare services required to health improvement. There should be adequate service provision so that patients receive their treatment as early as possible, pain and discomfort is well addressed, and physicians are well informed. Therefore, the patients are at risk of experiencing physical and emotional complications. One is the erosion of Fijians’ confidence in the health sector (Osunkwo et al. 2021). The subject of interest in this research will involve finding out about sickle cell patients’ experience in London. It will look into how they engage with such care receive and can inform suggestions for enhancement. Patient involvement will be used in determining the findings of the study.

Experience Of Sickle Cell Patients In Response To Quality Of Healthcare Provided In London assignment sample

Liked This Sample? Hire Me Now

Alan White 10 Years | MSc in Nursing

They will be employed in the form of policy analysis and patient satisfaction from other related research. Therefore, the outcome of this research is important to healthcare professionals and policymakers. The knowledge of patient experience can be useful for the further training of the medical staff and the improvement of the legislation in the industry. The findings of the research will also enable the enhancement of multi-professional working to enhance the lives of the patients. It adds to academic knowledge and practice for professionals in refining the quality of health care services for sufferers of sickle cell in London.

1.2 Literature review

1.2.1 Empirical study

Ofakunrin et al. 2024, studied the social and psychological effects of shielding on the SCD individuals and the carers in the Midlands, England. A clear evidence suggested the availability of viruses that affected the Midlands including Birmingham more especially because it was one of the areas with high mortality rates. From the results of the survey, patients with SCD benefited much from shielding, especially those who frequently visited the hospital. Mixed-methods design was employed. Questionnaire-survey was employed with an adapted SF36 V.2 form quantified participants’ mental health and quality of life. This was done through the use of qualitative semi structured questionnaires, through IPA analysis. A total of 51 out of the 135 participants completed the anonymous online questionnaire, the majority of them were Black Caribbean or Black African descendants (Ofakunrin et al. 2024). Adding to that, eight more discussions, focused on details, were conducted with the SCD adults.

Altogether, the outcomes revealed that SCD patients experienced a poor quality of life and mental health while in shielding. Many of the participant's concerns were regarding hospital attention, pain management, and professional knowledge about SCD. This brings evidence that racially related issues arising from the pandemic caused distress during research. The healthcare services have for most of the time not prioritized psychological health requisites. The study also underlines the need to enhance existing mental health services in patients with SCD especially during pandemic and within the broad health care (Ofakunrin et al. 2024). Sources of the study can be used to obtain the statistics in question.

Sickle cell anemia (SCA); another seriously known illness that caused frequent and severe crises demonstrated by Foster et al., 2024. In this qualitative literature review, the focus was also made to understand the experience of young people with SCA and its implications for functioning. This study evaluated the best primary research to give practice, education, and research implications. Articles were retrieved using the help of via EBSCOhost database. Applying the inclusion and exclusion criteria led to six relevant studies. About one’s age, a vast majority of participants were aged between 10-25 years. All the studies were conducted in the UK and in the USA (Foster et al., 2024). This is accompanied by the Critical Appraisal Skills Program (CASP) checklist which the current study used in order to review the quality of the research.

Therefore, this analysis led to the identification of the three main themes, ly acceptance, support, and unpredictability. Sub-themes were spirituality and discrimination. The study showed that SCA affected different spheres of youth life, including the educational, social life, and emotions. All of them had difficulties to recognize their disease, to receive proper treatment, and to deal with the uncertainty in the symptom progression. In view of this, the implication is to advance the practice of healthcare, increase awareness in school education, and explore deeper into SCA (Constantinou et al. 2024). It is very important to know the perception young people have so as to help them gain the best support they need and better policies on health that can be implemented for the improvement of their lives.

Patients with sickle cell disease were checked on a daily basis on a digital health platform regarding their perceptions of symptoms and daily QoL (Quality of Life) while using crizanlizumab. This preference-based measure was collected at baseline in the journal of Osunkwo et al. 2021, and after six months of treatment to compare their QoL scores before and after the intervention was applied. The results were that 60% of them had improved the QoL with an average of 28% increase in the EQ-5D scores. Of these, most reported that they wanted to complain less pain, better sleep and increased energy. On the other hand, 10% had even had the symptoms deteriorate, 30% had them either remain the same or improve slightly (Osunkwo et al. 2021). They who did not experience the improvement mentioned some additional difficulties such as fatigue, breathlessness, and joint pain, which states that this treatment’s impact is not the same for all patients.

Therefore, it states that actual tracking of development can be only ascertained through online health monitoring. It provides dynamic information on the nature of patients as well as the course of their treatment day by day. It has emphasized specialized care and subsequent research to determine several factors that might be the reason why some patients have better outcomes than others. The study thus provides evidence of the benefits of employing digital systems in evaluating sickle cell treatments and improving patient care.

Quality of Life in Sickle Cell Disease

The circulatory diseases like sickle cell anemia is a significant threat to health care and social systems in all the developed countries. Integrated care models and commonwealth interventions are useful in the improvement of the chronic patients. However, more studies are needed to identify whether these arrangements are helpful or not. Gavaldà-Espelta evaluated an Intracellular Calcium Mobilization (ICM) of health care and social service integration for a period of six months (Gavaldà-Espelta et al. 2023). An individual application was used to have regular interaction with fellow professionals. While patient reported outcomes were focused on the patients’ quality of life, treatment adherence, patient experience, and caregiver stress. The assessment was done at the start and end of the study, as well as six months after the intervention through the use of questionnaires.

Concerning the outcomes, it was found that the ICM helped in identifying new patients and enhancing provision of medical and social care. This led to the beneficiary outcomes such as, the lives of the patients also became healthier and they complied well with their treatments. Also, stress was reduced among the caregivers. These effects were sustained at least at the 6-month follow-up after the intervention. Analysis from this research emphasized the importance of integrated care as it increased the quality of the patients’ lives and their accessibility to the healthcare. It also reduced the burden of work on caregivers (Owoo and Tadros, 2022). Such applications and other technological advancements can possibly enhance a cohesion between health care and social services to eventually pave the way for a better long-term patient care and outcome.

Sickle cell disease (SCD) is an inherited haemoglobin disorder that numerous people in London. Among these Blacks and Caribbeans are most affected. According to a report published by the All-Party Parliamentary Group on Sickle Cell and Thalassaemia in 2021, the quality of care for the SCD is questionable. Also the delays in an adequate treatment regime and pain management is often commonly observed. Most patients complain of being ignored and therefore, they lack trust in healthcare facilities. Also, some cases were reported where felt outcasted or couldn’t get proper access to drug for their pain management. Such experiences compels the patients to neglect their illnesses that require medical attention, which in turn complicates their situation. Ongoing efforts are made to try and provide solutions such as new treatment plans and therapies to validate the setup. One such thing is gene therapy. Moreover, enhancing awareness against SCD among patients and practitioners can help resolve for SCD patients in London.

Sickle cell disease elimination

The study of Chakravorty et al. 2024, discussed the effect on improving health care quality for persons with hemoglobin disorders in the UK. In this research of Chakravorty et al. (2024), four (Splenic Sequestration Crisis) QS and reports between 2010 and 2020 have been observed. Its purpose was to establish whether the reviews made care more effective in haemoglobinopathy centers. Of the above highlighted centers, 17 were in the pediatric category while 29 were in the adult category and were inspected in the academic year 2010/11 and 2012/13. A total of 33 pediatric and 33 adult CACs (Chronic Anemia Crises) were visited in 2014/16. In evaluating the effectiveness of the intervention, data from the QS, views and experiences of the participants were taken into considerations.

Findings of the study showed that there was an increase in the level of compliance after the second review period. Virtually there are no improvements in the last review as revolution was expected to solve problems. Specifically, the haemoglobinopathy centers experienced some difficulty in responding to critical peer review recommendations in relation to other disease groups. This means that the improvements that were brought through peer reviews in the short term were not deliberate and sustained. This study underscored the need for sustaining the haemoglobinopathy service within the National Health Services. Thus, it is important for future works to analyze the positive response of some diseases to peer reviews as compared to the other diseases. Further research ought to explore better ways of enhancing the assurance of continued advancement of healthcare solutions in haemoglobinopathy.

From the empirical research of Redhead, 2021, it can be seen that, data that have actually been collected within a discipline to understand a given issue, which is Sickle cell anemia. Such research explores the concepts of race and health and its relevance and effects in SCA. The study engages medical activity in relation to black and migrant personnel in the NHS. This research rejected discrimination based on race in the treatment of patients through objection to the discrimination of patients with SCA (Redhead, 2021). It is an ailment common among African, South Asian, Middle Eastern, and Mediterranean individuals. The following are examples of such cases, one of them is the case of Stephen Bogle, a black person who had SCA and died due to neglect while in police custody.

It was seen that the NHS sidelined the needs related to the health of the black people and considered them as immigrants. They faced discrimination especially in the health policies that offer them anti-discriminatory integrated and clinical support for patients. Despite various challenges, immigration health practitioners were indeed one of the most important players that contributed towards the development of the NHS and helped in implementing healthcare policies without any racial discrimination (Ussher et al. 2025)

Diagnosis and management of Sickle cell disease

According to Munung et al. 2024, a research was conducted among 57 patients to study the impact of crizanlizmab on their hospitalization and emergency visits. All patients managed to have at least five admissions per year to the hospital for VOCs (Vaso-Occlusive Crisis) before undergoing the treatment. Among the population of participants, 35% experienced the decrease in the frequency of the hospital visits, and 22% of them stopped using emergency services within six months after the treatment. However, 30% of them required either same or more medical care, while 13% of them had more hospitalizations mainly due to side effects.

As demonstrated, the treatment plans had their side effects; therefore many of them reported having pain (27%), some experienced migraine (23%) while others suffered from fatigue (17%). Despite complications of treatment, 70% of patients planned that their general condition was enhanced, which indicated that the benefits of the therapy prevailed over all the negative effects in the majority of cases. The research showed that while most patients were saved from hospitalization with crizanlizumab; it was still less effective in this regard. Some patients still got admitted in hospital or developed other complications of the disease. This underlined the need for individual approaches to the therapy to further study the traits of disease that may influence the reactions to the medicine. Normally public gives different responses to sickle cell disease medicines. Due to the side effects it has on the body, some of the common symptoms include nausea, tiredness and dizziness. Some side effects of hydroxyurea include reduced number of blood cells or may lead hair loss. There are certain side effects drug effects like drowsiness and drug dependence on the substance that is used in the medication (Munung et al. 2024). Some of the patients also benefit from some outcomes such as reduction of pain crises. Interference risk and incidence are relative to individual measures and drug dosage.

SCD impacts management has not remained stagnant but rather it has gone to improved stages with advancement in the treatments. According to Grimbly et al., 2022, Crizanlizumab was approved in the year 2021 under managed access agreement. However, newer trials show that there has been no improvement in vaso-occlusive crisis as compared to placebo, it is important that further trials are conducted to really determine the safety and efficacy of deferiprone. This is because real-life experience is important to give a vivid account of the impact of bereavement leave policy on the lives of patients. This paper discusses SCD patient experiences with crizanlizumab. It focuses on side effects, signs and symptoms, hospital and bed utilization, and QoL (Quality of Life). The survey of 30 SCD patients received information about crizanlizumab through an online questionnaire. The EQ-5D-5L tool was used to assess daily overall QoL in a computerized system (Young et al. 2025). The data were collected from 10 patients before and after the administration of the treatment. They also compared their data with SCD patients on hydroxyurea and other SCD population. The patient was on crizanlizumab treatment for a mean of 6 months (Kunz et al. 2023).

The majority patients also received hydroxyurea. The participants’ mean age was 31 years and 77% of the participants were women. The minor side effects were pain at 27%, headaches, and fatigue at 23%. A statistically significant was recorded on the aspect of VOCs where 60% of patients reported an improved status from the initial baseline. However, 57% of them needed admission in the hospital and 70% were having VOCs. Results of QoL showed marked statistical significance (p<0.001) with overall enhancement in about 28% of the mean value. The patients also showed better quality of life and VOCs when they were given crizanlizumab as compared to the other three groups. Yet, the benefits were variable. There were those who developed no positive changes or even worsening of their condition (Dyal et al. 2021). Further research needs to be conducted to identify expected beneficiaries.

1.2.2. Theories and models

Health Belief Model (HBM):

According to the Health Belief Model (HBM), there are factors that shows why SCD patients fail to adhere to their treatment regimens. In this model people act when they can diagnose a disease as severe, they are defenseless and if they seek treatment, it will be for their good. Many SCD patients cease using hydroxyurea because of the poor understanding of the effectiveness of the drug or the availability of the related health services, including cost factor (Dyson et al. 2021). An effective way of enhancing the adherence is through raising awareness and availability of the treatment at an affordable price.

Biopsychosocial Model:

Apart from the Health Belief Model, focuses on the Biopsychosocial Model through which health is viewed under the biological, psychological and social models. The SCD patients suffer from various physical issues like pain and fatigue in addition to other conditions such as anxiety, and depression. Socially, they have challenges in managing their jobs, education and in the community, they are unknown to the public (Durgam et al. 2023). Therefore this model has a clear implication that SCD cannot and should not just be treated using physical ease but also emotional and social aspects.

Social Support Theory:

Apart from the above two, this is another theory which can be very effective for this research. The Social Support Theory establishes that there is improvement of a person’s well-being through increase of emotional and instrumental support. The SCD patients remain socially secluded after being diagnosed because most people in the society have no idea of what it means to have the condition. This means that they can always be supported by their family, friends, and their healthcare providers in case they find it hard to manage the condition (Pellegrini et al. 2023). The development of awareness programs and the support group can help to improve their quality of life and to handle such issues as problems of daily living.

Chapter 2: Methodology

2.1. Research Method and Strategy

In the current study, secondary research methodology was employed in order to investigate the perception that sickle cell patients had on health care in London. It involved data collection and accumulation as well as sorting of the data. Secondary research can be used in order to look for information and trends in previous research, reports and statistics. Information was obtained through research done in various articles, journal and scientific papers, reports and medical records, and surveys (Kavanagh et al. 2022). For these sources, only websites like the NHS, educational institutions, and health-focused organizations were employed. These sources were relevant because they were conducted in the UK.

The study focused on the experiences of the patients in hospital and the treatment of the minority patient, pain, and mental health of the patients. This is because comparing various sources allowed for detection of consistency in patients’ responses. There was no case of collecting individual data so as to guard or advance the interests of patients.

This paper relies on reports, journals, case studies as well as findings from the cross-sectional surveys and correlational designs. This enabled comparison of views and therefore degree of gap of health care services (Hood et al. 2022). The findings may help the policymakers in developing strategies, healthcare professionals in implementing quality care, and the researchers in developing up to date care options for the SCD patients.

2.2. Research design

In this research the design has been developed using the secondary research method and for that has developed effectively. It helped to gather any available information about the experience of Sickle Cell patients within the healthcare system in London. The study employed data from mark reports, patents and clients’ feedback, and health care policies as well as journal articles. In the course of conducting the study, data selection, analysis, and comparison were planned as the main strategies (Alvarez et al. 2023). First of all, the data from credible databases that included Medline and PubMed, the official body of government health reports and sickle cell organizations has helped a lot. Thirdly, the articles that considered the discussions with patients were included. Finally, an evaluation was made on the ability of the data working as a source of significant findings towards triumph healthcare issues.

This design was beneficial as it provided access to substantial information from various sources. From the evaluation of various studies the study provided an adequate account of patients’ experience (Thi Nhat Ho et al. 2019). The study design in the current work was useful in identifying healthcare service shortfall and providing information on how the healthcare services could be improved with a view of improving the patient care experience. The findings can help the healthcare givers, policy makers, and scholars of sickle cell patients within the London geographical region.

2.3. Research philosophy and approach

This study used the inductive approach and interpretivism research epistemology in order to capture the perceptions of sickle cell patients within London.

Inductive method

Inductive method entails data collection and then develops theory and patterns to be followed in dealing with issues. It does not presuppose theories in advance, which gives the possibility to study actual phenomena. Interpretivism examines people’s view on events rather than numbers and figures. It involves the aggregation of personal histories, examples, and meanings in an attempt to examine a patient’s conditions deeply.

Both were needed to grasp real-life problems and the patients’ perception of them. From the case, it can be deduced from the inductive methodology which means that the study commenced with the accumulation of data and followed by identification. This is in contrast to the development of a pre-determined theory which was not the case in generating knowledge for this research from the patient’s perspectives (Nwora et al. 2024). The research conducted through analyzing the reports from hospitals, patients’ experiences, and studies concerning the system proves that the healthcare system is almost overwhelmed by such problems as long waiting hours, pain management, and lack of access to treatment. This was helpful in making conclusions based on real facts rather than adopting certain hypotheses.

Interpretivism research philosophy

The study also adopted the interpretivism research philosophy. It helps in analyzing people’s lives rather than counts and percentages. The study involved the use of narratives, peoples’ individual and case studies as well as Web-based testimonies in an effort to establish how sickle cell patients perceive themselves and the difficulties they face. Therefore, there is evidence that the inductive approach and interpretivism proved to be essential for this research. The films enabled the viewers to recognize the social and psychological aspect of sickle cell disease (Dyal et al. 2021). This way the conclusions were derived from real patient experience, which allowed one to develop useful suggestions for improvement of the healthcare policies and support systems. The study was of a humanistic nature since it aimed at capturing data to allow for an understanding of sickle cell care from the sufferers’ perceptions.

2.4. Data collection

This research relied on paper-administered questionnaires and employed a research method that was of a qualitative nature. It embodied the findings of other research works, patients’ accounts, and other reports of sickle cell patients in London. All the information was derived from peer-reviewed articles, government health publications, and charitable nonprofit organizations. These sources enabled news into patients’ lives, how they were treated by hospitals, and various other issues relating to health (Oram et al. 2023). In the first step of the research, therefore, most of the scientific papers available in online sources, patient and hospital records were studied. It focused on the issues related to delays and lack of adequate number of specialists. Data for this study was obtained from records of non-profit Sickle Cell organisations and the National Health Service (NHS) supported the study’s findings. It has been identified that patient experiences were obtained from case reports, online questionnaires and customer account (Adigwe, 2023). These depictions highlighted such areas as pain and discrimination. Some of the issues that were highlighted in the course of comparison include late treatment. Secondary data in particular ensured ethical and effective research which extended the understanding of the problem. It may enhance the formulation of health decisions, and policies that will benefit the patients with sickle cell.

2.5. Research ethics

This research employed the use of paper-based questionnaires, thus it is a qualitative research. This study based on previous researches done on documents, stories of the sickle cell patients, health records about sickle cell disease in London. Sources of information included its medical literature, government health publications, and records from various charitable institutions. The findings from these sources helped in understanding the experiences of patient and treatments in the hospital as well as crucial issues in the health sector. The first approach of the study involved a review of the scholarly works and health reports and consumer and hospital feedback. It also described the deaths of some and the lack of appropriate treatment for others. Such records as those of Sickle Cell organizations and the NHS were used to support the study findings.

The issues of patient experience were gathered through case studies, online surveys, and from clients’ records. These revealed pain management problems and discrimination. This was due to comparing the results where options such as the fact that patients received delayed treatment were identified. Secondary data ensured ethical research. It maintained patient privacy. It avoided direct intervention. It provided broader insights. Possible implications to enhance the welfare of patients suffering from sickle cell anemia may additionally be stipulated by the findings.

Chapter 3: Result And Discussion

Sickle Cell Health Awareness

The results signify a very high level of concern among those with SCD in each of the age groups. Nonetheless, it should also be noted that around 79% of the young patients and 70% of the adults are concerned with the potential burden they pose on others. SCD is not considered a serious matter of concern in society as are other health concerns as evidenced by 83% of the young patients and 78% of the adult patients (Issom et al. 2021). It has the highest mean score of 3.57 concerning the issue about having children and children’s health. Currently, chronic diseases and illnesses hinder the patients from performing their work and education due to fear of suffering.

Treatment patterns and economic burden of SCD

The terms depicted illustrates treatment interventions in patients with sickle cell disease. The most commonly administered treatment is antibiotics at 77.6% to the patients. Folic acid ranks second at 75.1%. Oral non-selective NSAIDs including ibuprofen are administered to 55.5% of the patients. Pain is managed with opioids in 49% of the patients even though it is associated with severe pain. Ten percent of the patients receive the iron chelating therapy. The study recruited nearly 4,000 patients, all of them were treated with hydroxyurea (HU). Seventy-three point three percent of the patients were African American, and their mean age was 19.24 years. Therefore, by this idea about the SCD management can be gained effectively.

Therapeutic development for SCD

The figure is the development of SCD and this shows how SCD occurs in London and how it is managed. There is only one genetic mutation which leads to SCD, the substitution of the GAG triplet by GTG. It occurs due to the minimal modification because the main function affected is the production of red blood cells. The four sub-processes of this are shown in the following diagram where normal hemoglobin (HbA) becomes Sickle Hemoglobin (HbS) (Mishkin et al. 2023). These red blood cells and when they are let in by oxygen and then get deprived of this usable gas, they deform into a sickle shape. These sickle cells also have a tendency to form a mass on the blood vessels wall hence blocking the blood flow. In fact, for a long time up like 1980s, there was hardly any treatment at all. The patients required some treatments for serious issues blood transfusion, pain reliever as well as antibiotics.

Quality of Life in SCD

The illustrated figure (Quality of Life in SCD) is a pie chart depicting six parts which shows various issues affecting the quality of life to SCD patients. The parts include External Stressors like loss of job, family disputes, bills, child care, and health Complication. Chronic Pain which significantly raises negative thoughts such as low self-efficacy, catastrophizing, and self-doubt among the patients in London. The Perceived Stress is related to that fact where patients lack coping, social, assertive and problem-solving resources and in general that a patient is helpless, and can face serious issues due to this illness (Phillips et al. 2022). Depressed Mood/Anxiety involves bad/low morale, concern, and temperamental. Physiological arousal is when the patients have muscle tension, high adrenaline/cortisol level or lack of sleep. Pain Symptoms greatly include, pain not relieved, frequent hospitalizations, and opioids.

Age Groups Affected by SCD

The chart (Age Groups Affected by SCD) is labeled with different variations of health conditions on SCD patients based on age. They are Pneumonia and Acute Chest Syndrome, which affect 30-50% of every age group of SCD patients. These diseases affect children most, and their prevalence has been known to have affected 32 % of children who are in the age bracket of 6-17 years. It is well known that gallstones are most common in the young adults but their findings revealed that children in this age bracket had a 12% prevalence rate. In the case of the adults, this figure rises to 20 percent among those based in Greater London. Prolonged kidney ailment is a significant threat to the older generation, and more than forty percent of people above the age of fifty years are affected. Moreover, avascular necrosis, a bone ailment, becomes more frequent by age, and 20% of the patients represent the age between 30 and 50 years.

Multi-Ethnic Sickle Cell Patients

The graph shows two features of SCD patients, the anemic activity at a low partial pressure of oxygen and a normal or high RBC lifespan compared to normal people. The gross patient volumes by age and ethnicity can be seen part A. The largest group of patients is less than 5 years old, and then the percentage decreases progressively as age increases. Among the patients, African and African-American people are reported to be affected more than patients of other nationalities. Part B shows the Utilisation of HC, ATR, HC and ATR combinations amongst the different SCD’s. A total of 1,579 respondents across this study provided patient data, and the patients were almost divided between males and females with 802 and 777 respectively. The patient characteristics included age, gender, employment status, and ethnicity showed that the majority of the patients were of white (47.9%) or black (48.7%) origin.

3.1. Discussion

From figure 11 of result section (Sickle Cell Health Awareness), the situation described reveals significant tasks for the emotional and social adjustment of SCD patients. Besides, they lose approximately 7.5 days at work or school per month, this is a significant disruption in their daily life. The main concerns expressed are about pain crises, affecting 71% of sufferers and fatigue which affected 84% of the people asked. These affect their general quality of life. The participants stated that they need better ways of managing fatigue and more sources of information to share with the patients about the future risks. These data proves that individuals with SCD suffer not only from all sorts of physical problems but also suffer in various in the social and emotional aspects (Guarino et al. 2024). They think that society does not understand them and only 31% – 36% stated that the society understands them. This is an implication of poor recognition and endorsement of SCD patients in the public domain.

From the 12th figure of result section (Treatment patterns and economic burden of SCD), it shows that treatment of patients with SCD and the quality of the healthcare they receive are not at an adequate level. It may be due to patients stopping using hydroxyurea since 61 percent of those who use it cease from this medication. Additionally, those compliance with medication regime and prescription dose were 22.3 percent among the patients. It is concerning that medication adherence is poor on the part of the patients and this raises questions about the adequacy of follow up care and health care support offered.

The patients with SCD are said to require on average 13.35 days of hospitalization, which shows how dangerous the disease is. The costs include are also considerable in that patients incur an average of $27779 per annum in SCD related costs. The largest portion of this amount $20,128 is attributed to hospitalization other medical expenses are also taken into consideration (Ngonde et al. 2024). Meanwhile, asthma, acute chest Syndrome, infection, were among the other comorbidities with prevalence rates of 20.31%, 15.6% and 20% respectively. These co-existing conditions complicate treatment. Analgesia is significant in SCD treatment where a number of drugs like acetaminophen, NSAIDs, and opioids are used. This helped to establish the fact that the effective management of SCD is not an easy task at all.

From the 13th figure of result section (Therapeutic development for SCD), it can be seen that there are severe challenges in managing SCD especially in Nigeria where most of the new drugs have not arrived on the market. Despite the nature of FDA (Food and Drug Administration) having approved four different medications for the treatment of SCA, most patients cannot lay their hands on the drugs. In view of this, the research advocates for an exploration of functional foods as an alternative or complementary therapy for the Nigerian children (Grimbly et al. 2022). This may be particularly helpful where the new drugs are either unavailable or very expensive in their availability. This is why patients suffering from the disease get such acute symptoms as depicted in the diagram above. When red blood cells deform and aggregate themselves, they hinder circulation of blood. This is important especially so as to improve patient care particularly in places where new drugs are still unavailable.

Analysis of figure 14^th

From the 14th figure of result section (Quality of Life in SCD), the pie chart shows effects of SCD on the lives of patients in many diverse aspects. The concerns comprise of a loop. The meaning of this loop is that one concern leads to another. For instance, pain symptoms might lead to missed-working (external stressor) which leads to the concern with money (perceived stress) affecting depression & anxiety. It is also important to realize that despite the physical complaints, these certainly are subjective and are enmeshed with emotions and social factors. It can be deduced from the structure of the pie chart that each of them has an equivalent relevance with the quality of life. This leads to the view that efficient health care for SCD patients must address all of these, not just the physical illness. This means that patients need to be treated physically by providing necessary medications and psychologically by providing necessary mental support. Patients need to be relieved from pain, counseled for mental disorders, cared for on social front, given advice regarding their finances, given help to sleep and Show the right ways of handling stress.

From the 15th figure of result section (Age Groups Affected by SCD), it describes the progression of SCD complications and their onset from the period as the patients grow older. The young children suffers from mainly pneumonia or ACS while the elderly in London have more than one conditions at a time. The reason is evident in the fact that pneumonia / ACS is represented in all age groups and, therefore, respiratory treatment is to remain the priority. It is evident that the detection of the disease and monitoring of the kidneys’ functions are crucial as the people’s age increases. The text goes further to explain that SCD affects 300,000- 400,000 neonates globally and is most common. Counselling of this disease involves the use of hydroxycarbamide, blood transfusions together with stem cell transplants. This clearly shows that there exists an international variation concerning management of SCD. Given the anatomical and temporal involvement of SCD and its potential complications, comprehensive, life-course medical management and regular follow-ups of several potential complications are required.

From the 16th figure of result section (Multi-Ethnic Sickle Cell Patients), the data show considerable differences in SCD treatment by ethnic group. Emergency transfusion in patients was higher as compared to Caucasian patients. This might be attributed to a number of reasons such as: Hydroxycarbamide (HC) therapy being initiated later in the second group, Lower socioeconomic status that leads to limited access to health care services and Preferred Health care providers, and Potential bias in health care services. This indicated that 8.5% of the patients developed blood compatibility problems (alloimmunization), whereby the incidence was slightly higher in the Caucasian patients at 10.3% compared to the African patients at 6.6%. It was common in adults as compared to children. The findings focuses on the importance of compatibility in the transfusion process to avoid adverse effects. It can be described that this kind of disease needs early diagnosis and early treatment because most of the patients are school-age children.

Comparison of the secondary sources

It is evident from the results that there are many concerns for patients with SCD. The 11th figure of result section (Sickle Cell Health Awareness), involves features such as pain and fatigue which affects their school life and work in London. That is why many patients complain that society does not recognise them and they lack understanding and acknowledgement. While the 12th figure of result section (Treatment patterns and economic burden of SCD), shows the indication of low quality medical services (Martinez et al. 2020). These patients stop taking hydroxyurea and even those, who do continue taking medications, remain adherent to it. They also are costly because they require longer stays in the hospital, stressing more economic costs as well. In the course of the treatment Asthma and infections prove to be the greater challenge. Therefore, the research has shown that SCD patients need more assistance for them to adhere to their medication regime and manage the disease.

The 13th figure of result section (Therapeutic development for SCD) reveals great many difficulties in the treatment, especially in Nigeria. All of the sudden, several new medications are unavailable and the people are in desperate need for some sort of relief. The patients are equally meeting the consequences of scarce availability of medicine (Adesina et al. 2024).

The 14th figure of result section (Quality of Life in SCD) shows the life domains that are affected when having SCD. Pain leads to increase in stress levels, time off from work, and economic problems. In other words it means that both physical as well as mental treatment and attention is needed by the patients of London. Such an extensive view of the burden experienced by patients means that the healthcare providers are required not only to successfully address patients’ medical issues and modified illnesses, but also help to improve patients’ lives.

The 15th figure of result section (Age Groups Affected by SCD) describes how complications from SCD increase with age. While young patients mainly suffer from pneumonia, more than one illness affects the old patients. Screening should be done often, and if an individual experiences any pain at any one time, it is advisable to seek medical attention as early as possible. Newborn screening for early diagnosis is still a challenge especially in the developing countries.

The 16th figure of result section (Multi-Ethnic Sickle Cell Patients) compares ethnic group treatment. African patients require more emergency transfusions. Some of them develop complications associated with blood compatibility and thus call for better ways of matching blood. The indications include, increased health care facilities for patients, better initial care techniques, better matching of blood types and addressing negative healthcare disparities in London. This means that every patient requires the best diagnosis early enough and quality health care services.

Therefore, all this analysis helps to know the patients of SCD experience the healthcare quality in London. It can also help in the development of the treatment process.

Chapter 4: Conclusion

4. Conclusion

This last chapter, provides overall conclusion of the entire research work. The overall analysis of results and discussion can be seen in this chapter. Besides, this also provides recommendation focusing on which further research is possible.

4.1. Recommendation and future works

Improve Access to Specialist Care

A major problem in London where patients suffering from this disease do not have easy access to specialist physicians. There is a need to have an increased number of sickle cell clinics in the hospital and GPs to get more trained in the identification of this disease, sickle cell disease. Therefore, patients must have an appointment with a specialist without delay and there can’t be further postponements.

Reduce Waiting Times in Hospitals

Increased lengths of stay in the emergency departments contribute to the worsening of sickle cell crises. To ensure everyone with sickle cell is given attention, hospitals ought to set up ways of triaging patients. There is a need to increase the number of trained physicians and nurses in order to reduce on time delays. This means that by the use of scheduling work flow patients will be able to receive their check up on time.

Increase Need for Awareness and Training

Based on the results, it was revealed that most of the healthcare professionals have inadequate knowledge of sickle cell disease. Training for physicians and nurses has to be carried out in other sessions. This calls for the awareness campaigns to be conducted in schools, workplaces, communities and other social related assemblies. This will enhance provision of care and therefore helping individuals with sickle cell to manage their illness on a daily basis.

Improve Pain Management Strategies

Another problem that affected most of the sickle cell patients was pain. There are inadequate proposals for pain relief plans among hospitals. Conventional treatments include stronger pain killers, other types of treatment, and specialized pain clinic. The personalized pain management should be within the reach of the patients.

Strengthen Mental Health Support

Stress, anxiety and depression are some effects of, sickle cell disease. Coverage areas for health include more provision of mental health centres in the hospitals and clinics. Thus, one can mention support groups and free counseling sessions as helpful to patients to cope with the disease.

Medication and Treatment

Medication and treatment remain one of the greatest concerns in the lives of patients, especially those with chronic health conditions due to their high cost, which may be out of reach for many individuals who are struggling to afford their basic needs (Elendu et al. 2023). Some patients are struggling to access an innovative targeted therapy as crizanlizumab. These drugs should be made available easily through the NHS as they are important for the patients and also the health condition of the nation. This means that there is work that needs to be done to retain better therapeutic approaches that do not have severe side effects.

Future works

Researchers pointed out deficiencies that ought to be rectified including there being insufficient research on new treatments and their efficacy. Concerning the research, further efforts should be made in the development of individualized treatment intervention. Technology should be used in an attempt to measure the patients’ symptoms and optimize the treatments (Ahemad et al. 2022). In future studies, more emphasis should be placed on establishing how factors such as, social and economic are likely to influence hospital accessibility among Sickle Cell patients. Healthcare to the sickle cell patients in London should be enhanced through better policies, knowledge enhancement, and future research. This will lead to a more enhanced support of people and therefore have healthier individuals within the society.

Conclusion

When exploring the life patterns of the SCD patients, the quality healthcare in London, shows a lot issues like pain crises, fatigue, stress, etc. These problems are of great concern in their everyday lives, occupation, and academics. The study also showed that treatment and medication compliance level was very poor. About 41 % of the patients and this leads to an increased number of hospitalization. Moreover, the approximate average time spent in hospital is 13.35 days and average medical costs are annually. Due to the cost factor it is very difficult for the patients to bear the expenses. Other related findings that have been established include the following: Accessibility to health care was also found to be was a spirited issue. Ethnicity plays a significant role in determining treatment ad receiving of emergency services. They are in dire need of better treatment for pain, psychological as well as social support. Health care personnel have to face a various types of patients’ requirements, including physical and emotional needs. Therefore, early diagnosis, increased probability of treatment, proper patient counseling are crucial. The future generations of studies should therefore focus on improving of the health care policies and the search for more effective treatments for SCD patients.

References

Journals

• Adesina, O.O., Jenkins, I.C., Galvão, F., de Moura, A.C., Fertrin, K.Y., Zemel, B.S. and Saad, S.T.O., 2024. Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis. Osteoporosis International, pp.1-10.
• Ahemad, E., Mitchell, R., Goridari, M., Wood, I., Mahmood, S., O’Driscoll, S., Cortes, A. and Chakravorty, S., 2022. S128: Continuous quality improvement in paediatric sickle cell disease. HemaSphere, 6, pp.15-16.
• Alvarez, O.A., Rodriguez-Cortes, H., Clay, E.L.J., Echenique, S., Kanter, J., Strouse, J.J., Buitrago-Mogollon, T., Courtlandt, C., Noonan, L. and Osunkwo, I., 2023. Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia. BMJ quality & safety, 32(10), pp.608-616.
• Anie, K.A., 2024. The intersection of sickle cell disease, stigma, and pain in Africa. Hematology, 2024(1), pp.240-245.
• Chakravorty, S., Drasar, E., Kaya, B., Kesse‐Adu, R., Velangi, M., Wright, J. and Howard, J., 2024. UK Haemoglobin Disorders Peer Review: A Quality Standards‐based review programme for sickle cell disease and thalassaemia. British Journal of Haematology, 204(2), pp.668-676.
• Constantinou, C., Payne, N., van den Akker, O. and Inusa, B., 2024. Exploring health-related quality of life, exercise and alcohol use in adolescents with sickle cell disease and healthy siblings. Psychology & Health, pp.1-21.
• Crego, N., Masese, R., Bonnabeau, E., Douglas, C., Rains, G., Shah, N. and Tanabe, P., 2021. Patient perspectives of sickle cell management in the emergency department. Critical care nursing quarterly, 44(2), pp.160-174.
• Crusto, C.A., Kaufman, J.S., Harvanek, Z.M., Nelson, C. and Forray, A., 2024. Perceptions of Care and Perceived Discrimination: A Qualitative Assessment of Adults Living with Sickle Cell Disease. Journal of Racial and Ethnic Health Disparities, pp.1-10.
• de Montalembert, M., Anderson, A., Costa, F., Jastaniah, W., Kunz, J.B., Odame, I., Beaubrun, A., Lartey, B. and Inusa, B.P., 2022. P1487: Sickle Cell Health Awareness, Perspectives and Experiences (Shape) Survey: findings on the burden of sickle cell disease on patients and their unmet needs as reported by healthcare professionals. HemaSphere, 6, pp.1369-1370.
• Druye, A.A., Amoadu, M., Boso, C.M., Nabe, B., Kagbo, J.E., Alhassan, A., Odonkor, F.O., Lanyo, G.S., Davies, A.E., Doe, P.F. and Okantey, C., 2024. Self-management needs, strategies and support for individuals with sickle cell disease in developing countries: a scoping review. BMJ open, 14(9), p.e087723.
• Durgam, N., Brion, T., Lewis, H.B., Tinga, B., Sanon, W., Lundie, M. and Cadieux, C., 2023. Patient and caregiver perspectives on care-seeking during a vaso-occlusive crisis in sickle cell disease: Results from qualitative interviews in Canada. Patient Preference and adherence, pp.41-49.
• Dyal, B.W., Abudawood, K., Schoppee, T.M., Jean, S., Smith, V.M., Greenlee, A., Staton, L.M., Duckworth, L., Mandernach, M.W., Black, V. and Heldermon, C.D., 2021. Reflections of healthcare experiences of African Americans with sickle cell disease or cancer: a qualitative study. Cancer nursing, 44(1), pp.E53-E61.
• Dyson, S.M., Atkin, K.M., Berghs, M.J. and Greene, A.M., 2021. On the possibility of a disabled life in capitalist ruins: Black workers with sickle cell disorder in England. Social Science & Medicine, 272, p.113713.
• Gavaldà-Espelta, E., Maria, Jordi Baucells-Lluis, Ferré-Ferraté, M., Begoña Tomàs-Navarro, Curto-Romeu, C., Jorgina Lucas-Noll, Macarena Pozo Ariza, Elisabet Castro-Blanco, José Fernández Sáez, Carina Aguilar Martín, Alessandra Queiroga Gonçalves and Ferré-Grau, C. (2023). Innovative Health and Social Integrated Care Model Effectiveness to Improve Quality Care for Chronic Patients: A Single Group Assignment Clinical Trial. International Journal of Integrated Care, 23(4), pp. 1-16.
• Grimbly, C., Escagedo, P.D., Jaremko, J.L., Bruce, A., Alos, N., Robinson, M.E., Konji, V.N., Page, M., Scharke, M., Simpson, E. and Pastore, Y.D., 2022. Sickle cell bone disease and response to intravenous bisphosphonates in children. Osteoporosis International, 33(11), pp.2397-2408.
• Guarino, S.H., Bakare, O., Jenkins, C.M., Williams, K.D., Subedi, K., Wright, C.S., Pachter, L.M. and Lanzkron, S., 2024. Attitudes and Beliefs Regarding Pain and Discrimination Among Black Adults with Sickle Cell Disease: A Mixed Methods Evaluation of an Adapted Chronic Pain Intervention. Journal of Pain Research, pp.3601-3618.
• Haque, A. and Telfair, J. (2000). Socioeconomic Distress and Health Status: The Urban-rural Dichotomy of Services Utilization for People with Sickle Cell Disorder in North Carolina. The Journal of Rural Health, 16(1), pp.43–55.
• Hood, A.M., Crosby, L.E., Hanson, E., Shook, L.M., Lebensburger, J.D., Madan-Swain, A., Miller, M.M. and Trost, Z., 2022. The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease. Ethnicity & Health, 27(4), pp.833-846.
• Houwing, M.E., Buddenbaum, M., Verheul, T.C., de Pagter, A.P., Philipsen, J.N., Hazelzet, J.A. and Cnossen, M.H., 2021. Improving access to healthcare for paediatric sickle cell disease patients: a qualitative study on healthcare professionals’ views. BMC Health Services Research, 21, pp.1-13.
• Issom, D.Z., Hardy-Dessources, M.D., Romana, M., Hartvigsen, G. and Lovis, C., 2021. Toward a conversational agent to support the self-management of adults and young adults with sickle cell disease: usability and usefulness study. Frontiers in Digital Health, 3, p.600333.
• Jacob, S.A. and Yui, J.C., 2023. Moving the needle: using quality improvement to address gaps in sickle cell care. BMJ Quality & Safety, 32(10), pp.570-572.
• Jastaniah, W., Hartfield, R., James, J., Tinga, B., Ingoli, E., de Montalembert, M., Costa, F.F., Anderson, A.R., Kunz, J.B., Odame, I. and Lartey, B., 2023. Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) Survey: Findings on the Burden of Sickle Cell Disease and Impact on the Quality of Life of Patients and Caregivers in Gulf Cooperation Council Countries. Blood, 142, p.2516.
• Jastaniah, W., Hartfield, R., James, J., Tinga, B., Ingoli, E., de Montalembert, M., Costa, F.F., Anderson, A.R., Kunz, J.B., Odame, I. and Lartey, B., 2023. Sickle cell health awareness, perspectives, and experiences (SHAPE) survey: findings on the burden of sickle cell disease and impact on the quality of life of patients and caregivers in Gulf Cooperation Council countries. Blood, 142, p.2516.
• Kavanagh, P.L., Fasipe, T.A. and Wun, T., 2022. Sickle cell disease: a review. Jama, 328(1), pp.57-68.
• Kunz, J.B., de Montalembert, M., Costa, F.F., Jastaniah, W., Anderson, A., Odame, I., Lartey, B. and Inusa, B.P., 2023. Sickle cell health awareness, perspectives and experiences (SHAPE) survey: perspectives on sickle cell disease from physicians in Germany: P1060. Oncology Research and Treatment, 46, p.296.
• Martinez, R.M., Osei-Anto, H.A. and McCormick, M. (2020). Complications of Sickle Cell Disease and Current Management Approaches. www.ncbi.nlm.nih.gov. National Academies Press 113(2), pp.76-496.
• Meenan, J., Hall, R., Badle, S., Chatterjee, B., Win, N. and Tsitsikas, D.A., 2022. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far. Transfusion, 62(3), pp.546-550.
• Mishkin, A.D., Prince, E.J., Leimbach, E.J., Mapara, M.Y. and Carroll, C.P., 2023. Psychiatric comorbidities in adults with sickle cell disease: A narrative review. British journal of haematology, 203(5), pp.747-759.
• Munung, N.S., Treadwell, M., Kamga, K.K., Dennis-Antwi, J., Anie, K., Bukini, D., Makani, J. and Wonkam, A., 2024. Caught between pity, explicit bias, and discrimination: a qualitative study on the impact of stigma on the quality of life of persons living with sickle cell disease in three African countries. Quality of Life Research, 33(2), pp.423-432.
• Ngonde, A.-C.M., Fina, J.-P.L., Burgueno, E. and Lukanu, P.N. (2024). Knowledge and practices of sickle cell disease among healthcare providers in Kinshasa, Democratic Republic of the Congo. African Journal of Primary Health Care & Family Medicine, 16(1).
• Nwora, C., Prince, E.J., Pugh, L., Weaver, M.S. and Pecker, L.H., 2024. How young adults with sickle cell disease define “being a good patient” in the adult healthcare system. Pediatric Blood & Cancer, 71(2), p.e30786.
• Ofakunrin, A.O., Olaosebikan, R., Okpe, E.S., Diaku-Akinwumi, I., Babiker, S., Shehu, M. and Oguche, S., 2024. Barriers and Enablers to Hydroxyurea Adherence in Children and Adolescents with Sickle Cell Disease in Jos, Nigeria. Blood, 144, p.2517.
• Oram, S.H., Ei, S., Shankarghatta, R., Sathyanath, A., Hilary, B., Yeghen, T., Asher, S., Sharif, S. and Shastri, O., 2023. Effective Targeting of Evolutions in Concerns Underpinning COVID Vaccine Hesitancy in Patients with Sickle Cell Disease across the Lifespan of the COVID19 Pandemic. Blood, 142, p.2299.
• Osunkwo, I., Andemariam, B., Minniti, C.P., Inusa, B.P., El Rassi, F., Francis‐Gibson, B., Nero, A., Trimnell, C., Abboud, M.R., Arlet, J.B. and Colombatti, R., 2021. Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). American Journal of Hematology, 96(4), pp.404-417.